The first batch of IPOs in the new year failed to excite, but the IPO calendar continued to build last week as six companies set terms. The four completed deals were all energy-related...read more
EP Energy (EPE), an Apollo-backed oil and gas E&P focused on premier basins in Texas, Utah and Louisiana, raised $704 million by offering 35.2 million shares at $20. EP Energy now commands a market capitalization of $4.9 billion, which is large enough to...read more
EP Energy, an Apollo-backed oil and gas E&P focused on premier basins in TX, UT and LA, raised $704 million by offering 35.2 million shares (all primary) at $20, well below the range of $23 to $27. Formerly the E&P arm of El Paso, EP Energy was acquired...read more
The first full week of 2014 saw the most combined initial and terms filings since last June, while the first IPO of the year, by biotech GlycoMimetics (GLYC), posted a 13% gain. Four of the seven newly ...read more
US IPO Recap: Group of energy-related IPOs comes up dry
The first batch of IPOs in the new year failed to excite, but the IPO calendar continued to build last week as six companies set terms. The four completed deals were all energy-related...read more
EP Energy scheduled to enter the Renaissance IPO ETF (IPO)
EP Energy (EPE), an Apollo-backed oil and gas E&P focused on premier basins in Texas, Utah and Louisiana, raised $704 million by offering 35.2 million shares at $20. EP Energy now commands a market capitalization of $4.9 billion, which is large enough to...read more
Apollo's EP Energy prices downsized IPO at $20, below the $23-$27 range
EP Energy, an Apollo-backed oil and gas E&P focused on premier basins in TX, UT and LA, raised $704 million by offering 35.2 million shares (all primary) at $20, well below the range of $23 to $27. Formerly the E&P arm of El Paso, EP Energy was acquired...read more
US IPO Recap: Twenty companies file or set terms for IPOs
The first full week of 2014 saw the most combined initial and terms filings since last June, while the first IPO of the year, by biotech GlycoMimetics (GLYC), posted a 13% gain. Four of the seven newly ...read more